Zacks Research Issues Optimistic Forecast for UTHR Earnings

United Therapeutics Co. (NASDAQ:UTHR) – Investment analysts at Zacks Research boosted their FY2024 earnings estimates for shares of United Therapeutics in a report released on Tuesday, November 19th. Zacks Research analyst R. Department now expects that the biotechnology company will post earnings of $24.45 per share for the year, up from their previous forecast of $23.30. The consensus estimate for United Therapeutics’ current full-year earnings is $25.10 per share. Zacks Research also issued estimates for United Therapeutics’ Q1 2025 earnings at $6.93 EPS, Q2 2025 earnings at $6.63 EPS and Q2 2026 earnings at $6.47 EPS.

Other equities research analysts have also issued reports about the stock. Oppenheimer lifted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. TD Cowen boosted their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. The Goldman Sachs Group boosted their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. HC Wainwright boosted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Bank of America reduced their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Trading Up 0.8 %

Shares of United Therapeutics stock opened at $367.36 on Thursday. The firm has a market capitalization of $16.40 billion, a PE ratio of 16.13, a price-to-earnings-growth ratio of 1.05 and a beta of 0.56. The firm’s 50 day moving average is $364.39 and its 200 day moving average is $330.59. United Therapeutics has a 1 year low of $208.62 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the previous year, the company earned $5.38 EPS.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 224 shares of the company’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $412.28, for a total transaction of $92,350.72. Following the transaction, the director now owns 5,783 shares in the company, valued at approximately $2,384,215.24. This represents a 3.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Judy D. Olian sold 1,750 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $412.48, for a total transaction of $721,840.00. Following the transaction, the director now owns 5,655 shares in the company, valued at approximately $2,332,574.40. The trade was a 23.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 109,796 shares of company stock worth $40,936,370 in the last quarter. Company insiders own 11.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of UTHR. ClariVest Asset Management LLC raised its holdings in United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares during the last quarter. V Square Quantitative Management LLC acquired a new position in United Therapeutics during the second quarter worth $30,000. Innealta Capital LLC acquired a new position in United Therapeutics during the second quarter worth $33,000. USA Financial Formulas acquired a new position in United Therapeutics during the third quarter worth $33,000. Finally, Brooklyn Investment Group purchased a new stake in shares of United Therapeutics in the third quarter valued at about $33,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.